摘要
目的:评价中医药治疗非酒精性脂肪性肝病(Nonalcoholic Fatty Liver Disease,NAFLD)的有效性及安全性,探讨逍遥散加减方可能作用机制;验证肝脾相关理论的科学性。方法:选取非酒精性脂肪性肝病肝郁脾虚患者68例,符合全分析集(Full Analysis Sct,FAS)患者62例,其中逍遥散加减方组(试验组)37例,易善复组(对照组)25例,疗程均为8周,以治疗后ALT、AST、TC、TG、LDL-C、HDL-C、APN(Adiponectin)以及中医证候指标评价有效性,以及不良反应、实验室检查评价安全性。结果:治疗组血脂水平下降明显优于对照组,差异均有显著性意义(P<0.05)。治疗组ALT及AST水平明显低于对照组,APN水平明显高于对照组,差异均有显著性意义(P<0.05);治疗组中医症状积分下降优于对照组,差异有显著性意义(P<0.05);治疗组的综合疗效显著高于对照组。结论:逍遥散加减方可能是通过改善脂质代谢及提高脂联素的水平来发挥其抗NAFLD疗效的。
Objective： To evalute clinical effects and safety of TCM medicine on treating nonalcoholic fatty liver disease, and discuss mechanism of Xiaoyao San, to certify science of Ganpi Xiangguan theory. Methods： 68 patients were selected, 62 patients from full analysis sct were randomly divided into the treatment group （37 cases） and the control group （25 cases）. 8 weeks as the course.Effectiveness was evaluted by ALT, AST, TC, TG, LDL-C, HDL-C, APN and TCM syndrome indexes safety was evaluated by adverse reaction and laboratory examination. Results： The level of decreased lipid in the treatment was better than that in the control, the difference was statistically significant （P〈0.05）; ALT and AST level in the treatment were obviously lower than those in the control, APN level in thetreatment was obviously higher, the difference was statistically significant （P〈0.05）; TCM symptom score in the treatment declined better,the difference was statistically significant （P〈0.05）. The total efficacy in the treatment was higher. Conclusion： Xiaoyao San shows effects of anti NAFLD by improving lipid metabolism and the level of adiponectin.
出处
《中医临床研究》
2014年第29期3-4,10,共3页
Clinical Journal Of Chinese Medicine
